Henlius Pursues Two-Pronged Approach In Quest For Novel ADCs

Partnering And Independent

Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.

quest for success
Henlius's quest for novel ADCs under way • Source: Shutterstock

Amid surging enthusiasm for antibody-drug conjugates (ADCs) in China, Shanghai Henlius Biotech Co. Ltd., a biologics arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is taking an adventurous yet patient approach to the feverish local R&D in the field.

Key Takeaways

  • Henlius has taken its first decisive moves in the pursuit of ADC candidates possessing novel linker-payloads, with its EGFR-targeting HLX42 and PD-L1-targeting HLX43 cleared for trials in Chinese patients in October.

On one hand, some risk-averse Chinese ADC players have adopted a fast-follower approach to design linker-payload platforms, a key component...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia